Adverse reactions of Topiramate and Lamotrigine in children

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 3, 2005, Pages 187-192

  Shechter, Tamar ^a   Shorer, Zamir ^a,b   Kramer, Uri ^c,e   Lerman Sagie, Tally ^d,e   Ronen, Elisheva ^a,b   Rotem, Rimona ^a,b   Gorodischer, Rafael ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d WOLFSON MEDICAL CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adverse drug reaction; Anti convulsant drugs; Children; Lamotrigine; Topiramate

Indexed keywords

LAMOTRIGINE; TOPIRAMATE;

ADD ON THERAPY; ADOLESCENT; AGGRESSION; ANOREXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CHI SQUARE TEST; CHILD; DISEASE EXACERBATION; DISEASE SEVERITY; DROWSINESS; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; INFANT; ISRAEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NERVOUSNESS; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SPEECH DISORDER; STATISTICAL ANALYSIS; WEIGHT REDUCTION;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG MONITORING; DRUG THERAPY, COMBINATION; EATING DISORDERS; FATIGUE; FEMALE; FRUCTOSE; HUMANS; INFANT; MULTICENTER STUDIES; SLEEP STAGES; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES; WEIGHT LOSS;

EID: 14944347441     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1041     Document Type: Review

References (17)

1. Lasser KE, Allen PD, Woolhandle SJ, et al. Timing of new black box warning and withdrawals for prescription medications. JAMA 2002; 287(17): 2215-2220.
2. Choonara I, Gill A, Nunn A. Drug toxicity and surveillance in children. Br J Clin Pharmacol 1996; 42: 407-410.
3. Topiramate (TOPAMAX®) Product Information. Ortho-McNeil Pharmaceuticals, Inc. Raritan, NJ 08869, June 2003.
4. Mikaeloff Y, Saint-Martin A, Mancini J. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003; 53(3): 225-232.
5. Ortho-McNeil Pharmaceuticals, Inc. Raritan, NJ 08869, Important Drug Warning, September 26, 2001.
6. Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002; 43(7): 744-747.
7. Ortho-McNeil Pharmaceuticals, Inc. Raritan, NJ 08869, Important Drug Warning, July 2003.
8. Messenheimer JA, Giorgi L, Risner ME. The tolerability of Lamotrigine in children. Drug Saf 2000; 22(4): 303-312.
9. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35(2): 359-367.
10. Duchowny M, Gilman J, Messenheimer J, et al. Long-term tolerability and efficacy of Lamotrigine in paediatric patients with epilepsy. J Child Neurol 2002; 17(4): 278-285.
11. Besag FM, Dulac O, Alving J, et al. Long-term safety and efficacy of Lamotrigine (Lamictal) in paediatric patients with epilepsy. Seizures 1997; 6(1): 51-56.
12. Mikati MA, Fayed M, Koleilat M, et al. Efficacy, tolerability and kinetics of Lamotrigine in infants. J Pediatr 2002; 141(1): 31-35.
13. Lamotrigine (Lamictal®) product information. Glaxo-Wellcome, Inc. Research Triangle Park, NC 27709. November 1998.
14. Fayed M, Choueiri R, Mikati M. Potential hepatotoxicity of Lamotrigine. Pediatr Neurol 2000; 22: 49-52.
15. Sotero-de-Menezes MA, Rho JM, Murphy P, et al. Lamotrigine-induced tic disorder: report of five paediatric cases. Epilepsia 2000; 41(7): 862-867.
16. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002; 87: 462-467.
17. Besag FM. Behavioral effects of the new anticonvulsants. Drug Saf2001; 24(7): 513-536.